Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer's Disease

An investigational drug (MK0677) will be studied to determine whether it helps the memory and cognition of patients with Alzheimer's Disease.

• Patients must have probable Alzheimer's disease of mild or moderate severity.
• A brain scan and laboratory results must be consistent with Alzheimer's disease.
• The patient must be otherwise medically healthy.